Whitepapers

Visionary medicine: the future of glaucoma treatments

Our new whitepaper explores how conventional treatments (surgical and medicine-based) tackle existing challenges of the conditions, and the limitations they face.

ophthalmic instruments, glaucoma, macular degeneration
ophthalmic instruments, glaucoma, macular degeneration

Glaucoma screening: a global perspective

What are the risk factors for glaucoma and how can identifying them guide creation of robust screening programmes?

60 million people live with glaucoma worldwide, and close to 5 million people are blind from open angle glaucoma. Glaucoma is prevalent and presents many challenges for the eye health industry. Our whitepaper examines open angle and angle closure glaucoma from a global perspective , looking at:

  • The prevalance of glaucoma
  • Genetic and age-related risk factors
  • Glaucoma screening in practice

Age-related macular degeneration: the case for early screening

Our whitepaper explores the development of AMD and helps you to understand the key risk factors. Our analysis spans non-modifiable risk factors such as family history and genetic, as well as modifiable factors like smoking, diet and BMI.

Read our paper for insights into:

  • The academic case for targeted screening
  • Lifestyle factors affecting AMD development
  • Understanding wet and dry AMD
  • How ophthalmologists can raise awareness of AMD
ophthalmic instruments, glaucoma, macular degeneration
ophthalmic instruments, glaucoma, macular degeneration

The use of MPS ll as part of a macular screening programme

Prevention is better than intervention

This whitepaper outlines pragmatic guidelines for a coherent strategy around the prevention and management of age-related macular degeneration (AMD).

Written by Dr. Scott Mackie, a Consultant Ophthalmologist, supported by Elektron Eye Technology.